Skip to content

Daniel Ortwine

  • BS
  • Principal Scientist
  • Genentech Inc
  • 29h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 2637CitationsNumber of citations received by Daniel's publications. Updated daily.

Other IDs

Research interests

Computational chemistry

Co-authors (482)

Publications (5)

  • Computational Support of Medicinal Chemistry in Industrial Settings

    • Ortwine D
    N/AReaders
    N/ACitations
    Get full text
  • Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors

    • Chernov-Rogan T
    • Li T
    • Lu G
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors

    • Labadie S
    • Dragovich P
    • Cummings R
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies

    • Liang J
    • Zhang B
    • Labadie S
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant ac

    • Bigge C
    • Malone T
    • Boxer P
    • et al.
    N/AReaders
    N/ACitations
    Get full text

Professional experience

Principal Scientist

Genentech

August 2007 - Present

Research Fellow

Pfizer

September 1976 - April 2007(31 years)